中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

19 records (took 0.016 seconds)

    METHODS OF USING IL-1 ANTAGONISTS TO TREAT AUTOINFLAMMATORY DISEASE
    1.
    发明申请
    METHODS OF USING IL-1 ANTAGONISTS TO TREAT AUTOINFLAMMATORY DISEASE 有权
    使用IL-1拮抗剂治疗自身免疫性疾病的方法

    公开(公告)号：US20110318342A1

    公开(公告)日：2011-12-29

    申请号：US13224372

    申请日：2011-09-02

    Applicant: Scott Mellis ,  Margaret Karow ,  George D. Yancopoulos ,  Joanne Papadopoulos

    Inventor： Scott Mellis ,  Margaret Karow ,  George D. Yancopoulos ,  Joanne Papadopoulos

    IPC: A61K39/395 ,  A61K38/48 ,  A61P37/06 ,  A61K38/16

    CPC classification number: C07K14/7155 ,  A61K38/00 ,  A61K38/177 ,  A61K45/06 ,  A61K2300/00

    Abstract: Methods of treating, inhibiting, or ameliorating an autoinflammatory disorder, disease, or condition in a subject in need thereof, comprising administering to a subject in need a therapeutic amount of an interleukin 1 (IL-1) antagonist, wherein the autoinflammatory disorder, disease, or condition is treated, inhibited, or ameliorated. The IL-1 antagonist is a molecule capable of binding and inhibiting IL-1. The therapeutic methods are useful for treating a human adult or child suffering from Neonatal Onset Multisystem Inflammatory Disorder (NOMID/CINCA), Muckle-Wells Syndrome (MWS), Familial Cold Autoinflammatory Syndrome (FCAS), familial mediterranean fever (FMF), tumor necrosis factor receptor-associated periodic fever syndrome (TRAPS), or systemic onset juvenile idiopathic arthritis (Still's Disease).

    Abstract translation: 在有需要的受试者中治疗，抑制或改善自身炎性疾病，疾病或病症的方法，包括向需要治疗的受试者施用治疗量的白细胞介素1（IL-1）拮抗剂，其中所述自身炎性疾病，疾病 ，或条件得到治疗，抑制或改善。 IL-1拮抗剂是能够结合和抑制IL-1的分子。 治疗方法可用于治疗患有新生儿起始多系统炎症性疾病（NOMID / CINCA），Muckle-Wells综合征（MWS），家族性冷自身炎症综合征（FCAS），家族性地中海热（FMF），肿瘤坏死的成人或儿童 因子受体相关的周期性发热综合征（TRAPS）或全身性发作的幼年特发性关节炎（Still氏病）。

    Methods for identifying a candidate for treatment of obesity
    4.
    发明申请
    Methods for identifying a candidate for treatment of obesity 有权
    识别肥胖症治疗候选人的方法

    公开(公告)号：US20060008832A1

    公开(公告)日：2006-01-12

    申请号：US11177860

    申请日：2005-07-08

    Applicant: Scott Mellis

    Inventor： Scott Mellis

    IPC: C12Q1/68

    CPC classification number: C12Q1/6883 ,  C12Q1/6881 ,  C12Q2600/106 ,  C12Q2600/156

    Abstract: Methods of identifying human subjects for treatment of obesity or an obesity-related condition with ciliary neurotrophic factor (CNTF) or a CNTF-related molecule, such as Axokine®, based on the presence of human leukocyte antigen (HLA) DRβ1 allele 1501 or the absence of HLA DRβ1 allele 0701.

    Abstract translation: 基于人白细胞抗原（HLA）DRbeta1等位基因1501的存在，鉴定用于治疗肥胖或与睫状神经营养因子（CNTF）或CNTF相关分子（例如Axokine）的肥胖相关状况的人类受试者的方法 或不存在HLA DRbeta1等位基因0701。

    METHODS OF USING IL-1 ANTAGONISTS TO TREAT FAMILIAL MEDITERRANEAN FEVER (FMF)
    7.
    发明申请
    METHODS OF USING IL-1 ANTAGONISTS TO TREAT FAMILIAL MEDITERRANEAN FEVER (FMF) 审中-公开
    使用IL-1拮抗剂治疗家族中性粒细胞（FMF）的方法

    公开(公告)号：US20110311537A1

    公开(公告)日：2011-12-22

    申请号：US13222759

    申请日：2011-08-31

    Applicant: SCOTT MELLIS ,  MARGARET KAROW ,  GEORGE D. YANCOPOULOS ,  JOANNE PAPADOPOULOS

    Inventor： SCOTT MELLIS ,  MARGARET KAROW ,  GEORGE D. YANCOPOULOS ,  JOANNE PAPADOPOULOS

    IPC: A61K39/395 ,  A61P29/00

    CPC classification number: C07K14/7155 ,  A61K38/00 ,  A61K38/177 ,  A61K45/06 ,  A61K2300/00

    Abstract: Methods of treating, inhibiting, or ameliorating Familial Mediterranean Fever (FMF) by administering to a subject in need thereof a therapeutically effective amount of an interleukin 1 (IL-1) antagonist, are provided. The IL-1 antagonist can be an antibody or derivative thereof, which is capable of blocking or inhibiting the biological action of IL-1, thereby treating, inhibiting or ameliorating FMF. Also provided are methods of treating, inhibiting, or ameliorating FMF by administering a therapeutically effective amount of an IL-1 antagonist in combination with additional therapeutic agents, including IL-1-specific fusion proteins, TNF inhibitors, NSAIDs, steroids, and the like.

    Abstract translation: 提供了通过向有需要的受试者施用治疗有效量的白细胞介素1（IL-1）拮抗剂来治疗，抑制或改善家族性地中海热（FMF）的方法。 IL-1拮抗剂可以是抗体或其衍生物，其能够阻断或抑制IL-1的生物学作用，从而治疗，抑制或改善FMF。 还提供了通过将治疗有效量的IL-1拮抗剂与另外的治疗剂（包括IL-1特异性融合蛋白，TNF抑制剂，NSAID，类固醇等）组合施用来治疗，抑制或改善FMF的方法 。

    Methods of Using IL-1 Antagonists to Treat Autoinflammatory Disease
    10.
    发明申请
    Methods of Using IL-1 Antagonists to Treat Autoinflammatory Disease 审中-公开
    使用IL-1拮抗剂治疗自身炎症性疾病的方法

    公开(公告)号：US20090156492A1

    公开(公告)日：2009-06-18

    申请号：US12259366

    申请日：2008-10-28

    Applicant: Scott Mellis ,  Margaret Karow ,  George D. Yancopoulos ,  Joanne Papadopoulos

    Inventor： Scott Mellis ,  Margaret Karow ,  George D. Yancopoulos ,  Joanne Papadopoulos

    IPC: A61K38/17 ,  A61P29/00

    CPC classification number: C07K14/7155 ,  A61K38/00 ,  A61K38/177 ,  A61K45/06 ,  A61K2300/00

    Abstract: Methods of treating, inhibiting, or ameliorating an autoinflammatory disorder, disease, or condition in a subject in need thereof, comprising administering to a subject in need a therapeutic amount of an interleukin 1 (IL-1) antagonist, wherein the autoinflammatory disorder, disease, or condition is treated, inhibited, or ameliorated. The IL-1 antagonist is an IL-1 trap, preferably comprising a sequence selected from the group consisting of SEQ ID NO: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, or a substantially identical having at least 95% identity to the sequence shown in SEQ ID NO: 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 and capable of binding and inhibiting IL-1. The therapeutic methods are useful for treating a human adult or child suffering from Neonatal Onset Multisystem Inflammatory Disorder (NOMID/CINCA), Muckle-Wells Syndrome (MWS), Familial Cold Autoinflammatory Syndrome (FCAS), familial mediterranean fever (FMF), or systemic onset juvenile rheumatoid arthritis (Still's Disease).

    Abstract translation: 在有需要的受试者中治疗，抑制或改善自身炎性疾病，疾病或病症的方法，包括向需要治疗的受试者施用治疗量的白细胞介素1（IL-1）拮抗剂，其中所述自身炎性疾病，疾病 ，或条件得到治疗，抑制或改善。 IL-1拮抗剂是IL-1捕获物，优选包含选自SEQ ID NO：4,6,8,10,12,14,16,18,20,22,24,26， 或与SEQ ID NO：4,6,8,10,12,14,16,18,20,22,24,26中所示的序列具有至少95％的同一性，并能够结合和抑制IL- 1。 治疗方法可用于治疗患有新生儿起始多系统炎症性疾病（NOMID / CINCA），Muckle-Wells综合征（MWS），家族性冷自身炎症综合征（FCAS），家族性地中海热（FMF）或全身性 发病青少年类风湿关节炎（Still氏病）。

Patent Agency Ranking